Share

December 2016; 2 (6) Clinical/Scientific NotesOpen Access

Mitochondrial cytopathy with common MELAS mutation presenting as multiple system atrophy mimic

Anne-Katrin Pröbstel, André Schaller, Johanna Lieb, Juergen Hench, Stephan Frank, Peter Fuhr, Ludwig Kappos, Michael Sinnreich
First published November 17, 2016, DOI: https://doi.org/10.1212/NXG.0000000000000121
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
0

Share

Article Information

vol. 2 no. 6 e121
DOI: 
https://doi.org/10.1212/NXG.0000000000000121
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Online ISSN: 
2376-7839
History: 
  • Received July 12, 2016
  • Accepted in final form October 20, 2016
  • First Published November 17, 2016.
Copyright & Usage: 
© 2016 American Academy of Neurology This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Author Disclosures

    1. Anne-Katrin Pröbstel, MD,
    2. André Schaller, PhD,
    3. Johanna Lieb, MD,
    4. Juergen Hench, MD,
    5. Stephan Frank, MD,
    6. Peter Fuhr, MD,
    7. Ludwig Kappos, MD and
    8. Michael Sinnreich, MD, PhD
  1. Anne-Katrin Pröbstel, MD,
    2. Scientific Advisory Boards:

    1. Dr. Pr?bstel has served on the scientific advisory board of Bayer.

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Dr. Pr?bstel received research support from Genzyme.

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. Dr. Pr?bstel received research funding from University of Basel.

    Research Support, Foundations and Societies:

    1. Dr. Pr?bstel received research funding from the Swiss National Science Foundation.

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. André Schaller, PhD,
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. (1)Novartis Foundation for medical-biological researchdiscussed your application nr. 16B130 ?Molecularcharacterisation of mitochondrial disorders?

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Johanna Lieb, MD,
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Juergen Hench, MD,
    5. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Stephan Frank, MD,
    6. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  6. Peter Fuhr, MD,
    7. Scientific Advisory Boards:

    1. (1)General Electrics: Advisory Board (2)UCB: Advisory Board (3)Biogen: Advisory Board

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical procedures or imaging studies:

    1. 30% Clinic for and research in Movement Disorders, University Hospital of Basel, Switzerland 50% Section of Clinical Neurophysiology (clinical application and Research), University Hospital of Basel, Switzerland 20% General Neurology and Administration, University Hospital of Basel, Switzerland

    Research Support, Commercial Entities:

    1. (1) Roche (2) AbbVie (3) General Electric (4) Biogen

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. (1) Swiss National Science Foundation

    Research Support, Foundations and Societies:

    1. (1) Synapsis Foundation; principle investigator; 2009-2011 (2) Gossweiler Foundation; principle investigator; 2011- 2012 (3) Botnar Foundation; principle investigator; 2012-2015 (4) Parkinson Association Switzerland; principle investigator, 2010-2012 (5) Parkinson Association Switzerland; principle investigator, 2013-2014 (6) Mach-Gaensslen Foundation; principle investigator, 2012-2014 (7) Gottfried and Julia Bangerter-Rhyner Foundation; principle investigator, 2013-2014

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  7. Ludwig Kappos, MD and
    8. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. (1)Multiple Sclerosis Journal, (2)Multiple Sclerosis and Related Disorders (3)Journal of Neurology member of the Editorial Board

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1)Actelion, (2)Alkermes, (3)Almirall, (4)Bayer, (5)Biogen, (6)Excemed, (7)GeNeuro SA, (8)Genzyme, (9)Merck, (10)Mitsubishi Pharma, (11)Novartis, (12)Receptos, (13)Roche, (14)sanofi-aventis, (15)Santhera, (16)Teva, (17)Vianex

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. (1)the Swiss MS Society, (2)the Swiss National Research Foundation, (3)the European Union, (4)Roche Research Foundations

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License fee payments, Technology or Inventions:

    1. (1) license fees for Neurostatus products paid directly to University Hospital Basel

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  8. Michael Sinnreich, MD, PhD
    9. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Institution received speaker honoraria from Novartis and Mepha for CME activities, which were used exclusively for research support.

    Editorial Boards:

    1. Acta Myologica, Editorial board

    Patents:

    1. A method for evaluating a candidate compound for treating Myotonic Dystrophy type 1 (DM1).

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical procedures or imaging studies:

    1. University Hospital Basel, Neurology Clinic and Neuromuscular Research, 100% effort, 2009 - present

    Research Support, Commercial Entities:

    1. Institution received research support from CSL Behring and Roche

    Research Support, Government Entities:

    1. Swiss National Science Foundation, grant number 31003A_146359, principal investigator

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. (1) Gebert-Ruef Foundation (2) Uniscientia Foundation (3) Neuromuscular Research Association Basel (4) Myosuisse

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. Novartis, 2014 - 2016 Roche, 2014 - 2015, March

    Legal Proceedings:

    1. NONE

  1. From the Neurologic Clinic and Policlinic (A.-K.P., P.F., L.K., M.S.), Departments of Medicine and Biomedicine; Division of Neuroradiology (J.L.), Department of Radiology; and Division of Neuropathology (J.H., S.F.), Department of Pathology, University Hospital Basel, University of Basel, Switzerland; Division of Human Genetics (A.S.), Department of Pediatrics, Inselspital, Bern University Hospital, University of Bern, Switzerland.
  1. Correspondence to Dr. Sinnreich: Michael.Sinnreich{at}usb.ch
View Full Text

Article usage

Article usage: November 2016 to August 2022

AbstractFullPdfSource
Nov 2016792922Highwire
Dec 201615431155Highwire
Jan 20177722322Highwire
Feb 201725176Highwire
Mar 2017361614Highwire
Apr 2017211516Highwire
May 2017271410Highwire
Jun 20179124Highwire
Jul 201718137Highwire
Aug 201713241Highwire
Sep 20179133Highwire
Oct 20171297Highwire
Nov 201716268Highwire
Dec 201732612Highwire
Jan 201871516Highwire
Feb 20183199Highwire
Mar 20185225Highwire
Apr 201832813Highwire
May 20184249Highwire
Jun 20185398Highwire
Jul 20185378Highwire
Aug 201852810Highwire
Sep 201841811Highwire
Oct 201843710Highwire
Nov 20184698Highwire
Dec 20184808Highwire
Jan 201945511Highwire
Feb 20196638Highwire
Mar 20194399Highwire
Apr 20197259Highwire
May 201952212Highwire
Jun 201921911Highwire
Jul 201962614Highwire
Aug 201942560Highwire
Sep 201922827Highwire
Oct 201932412Highwire
Nov 201911914Highwire
Dec 20194308Highwire
Jan 20203265Highwire
Feb 20202208Highwire
Mar 202013313Highwire
Apr 20201173Highwire
May 20201207Highwire
Jun 20201135Highwire
Jul 202011819Highwire
Aug 20200205Highwire
Sep 20200273Highwire
Oct 202021112Highwire
Nov 20201154Highwire
Dec 202012114Highwire
Jan 20210816Highwire
Feb 20211107Highwire
Mar 20210119Highwire
Apr 20210224Highwire
May 202123411Highwire
Jun 20211226Highwire
Jul 202122115Highwire
Aug 20214189Highwire
Sep 20210215Highwire
Oct 202111720Highwire
Nov 202102312Highwire
Dec 20211187Highwire
Jan 20221193Highwire
Feb 20221158Highwire
Mar 20220256Highwire
Apr 20220231Highwire
May 202213412Highwire
Jun 20220409Highwire
Jul 20220194Highwire
Aug 20221466Highwire

Letters: Rapid online correspondence

Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top

Related Articles

  • No related articles found.

Alert Me

Advertisement